Hepatitis Monthly

Published by: Kowsar

Reactivation of Hepatitis B Virus During Treatment of Hepatitis C Genotype 3 with Daclatasvir and Sofosbuvir in a Patient with Dual Infection of Hepatitis B and Hepatitis C Virus

Georgios Zacharakis 1 , 2 , * and Jaman Alzahrani 2
Authors Information
1 Endoscopy Unit, Limassol General Hospital and St George’s University of London Medical School at the University of Nicosia, Republic of Cyprus
2 Department of Internal Medicine, University Hospital, Prince Sattam Bin Abdulaziz University, Al Kharj, KSA
Article information
  • Hepatitis Monthly: January 2018, 18 (1); e12531
  • Published Online: January 20, 2018
  • Article Type: Case Report
  • Received: May 4, 2017
  • Revised: September 16, 2017
  • Accepted: December 24, 2017
  • DOI: 10.5812/hepatmon.12531

To Cite: Zacharakis G, Alzahrani J. Reactivation of Hepatitis B Virus During Treatment of Hepatitis C Genotype 3 with Daclatasvir and Sofosbuvir in a Patient with Dual Infection of Hepatitis B and Hepatitis C Virus, Hepat Mon. 2018 ; 18(1):e12531. doi: 10.5812/hepatmon.12531.

Copyright © 2018, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Case Presentation
3. Discussion
  • 1. Sagnelli E, Pisaturo M, Martini S, Sagnelli C, Filippini P, Coppola N. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. Expert Opin Pharmacother. 2014;15(10):1337-49. doi: 10.1517/14656566.2014.913571. [PubMed: 24773464].
  • 2. Sato S, Fujiyama S, Tanaka M, Yamasaki K, Kuramoto I, Kawano S, et al. Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. J Hepatol. 1994;21(2):159-66. doi: 10.1016/S0168-8278(05)80389-7. [PubMed: 7527435].
  • 3. Lee LP, Dai CY, Chuang WL, Chang WY, Hou NJ, Hsieh MY, et al. Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients. J Gastroenterol Hepatol. 2007;22(4):515-7. doi: 10.1111/j.1440-1746.2006.04547.x. [PubMed: 17376043].
  • 4. Sagnelli E, Coppola N, Pisaturo M, Masiello A, Tonziello G, Sagnelli C, et al. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology. 2009;49(4):1090-7. doi: 10.1002/hep.22794. [PubMed: 19263473].
  • 5. Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol. 1998;28(1):27-33. doi: 10.1016/S0168-8278(98)80198-0. [PubMed: 9537860].
  • 6. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 1998;75(3):347-54. doi: 10.1002/(SICI)1097-0215(19980130)75:3<347::AID-IJC4>3.0.CO;2-2. [PubMed: 9455792].
  • 7. Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer. 2005;92(3):607-12. doi: 10.1038/sj.bjc.6602333. [PubMed: 15685242].
  • 8. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998;28(6):1687-95. doi: 10.1002/hep.510280632. [PubMed: 9828236].
  • 9. Pol S, Lucier S, Fontaine H, Dorival C, Petrov-Sanchez V, Bourlière M, et al. P0468 : Negative impact of HBV/HCV coinfection on HBV or HCV monoinfection: Data from the French cohort – ANRS CO22 hepather. J Hepatol. 2015;62:488-9. doi: 10.1016/s0168-8278(15)30676-0.
  • 10. European Association for the Study of the Liver. Electronic address EEE. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66(1):153-94. doi: 10.1016/j.jhep.2016.09.001. [PubMed: 27667367].
  • 11. Aasld Idsa Hcv Guidance Panel . Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932-54. doi: 10.1002/hep.27950. [PubMed: 26111063].
  • 12. Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98.
  • 13. Potthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, et al. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol. 2008;49(5):688-94. doi: 10.1016/j.jhep.2008.03.028. [PubMed: 18490077].
  • 14. Hamzaoui L, El Bouchtili S, Siai K, Mahmoudi M, Azzouz MM. Hepatitis B virus and hepatitis C virus co-infection: a therapeutic challenge. Clin Res Hepatol Gastroenterol. 2013;37(1):e16-20. doi: 10.1016/j.clinre.2012.08.001. [PubMed: 22959099].
  • 15. Takayama H, Sato T, Ikeda F, Fujiki S. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res. 2016;46(5):489-91. doi: 10.1111/hepr.12578. [PubMed: 26297529].
  • 16. De Monte A, Courjon J, Anty R, Cua E, Naqvi A, Mondain V, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol. 2016;78:27-30. doi: 10.1016/j.jcv.2016.02.026. [PubMed: 26967675].
  • 17. Collins JM, Raphael KL, Terry C, Cartwright EJ, Pillai A, Anania FA, et al. Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. Clin Infect Dis. 2015;61(8):1304-6. doi: 10.1093/cid/civ474. [PubMed: 26082511].
  • 18. Ende AR, Kim NH, Yeh MM, Harper J, Landis CS. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep. 2015;9:164. doi: 10.1186/s13256-015-0630-8. [PubMed: 26215390].
  • 19. Kimura H, Ohkawa K, Sakakibara M, Imanaka K, Matsunaga T, Miyazaki M, et al. Sustained hepatitis C virus RNA clearance accompanied by elevation of hepatitis B virus DNA after short-term peginterferon-α, ribavirin and simeprevir therapy in a chronic hepatitis patient having dual infection with hepatitis B and C viruses. Kanzo. 2015;56(8):422-7. doi: 10.2957/kanzo.56.422.
  • 20. Bersoff-Matcha SJ, Cao K, Jason M, Ajao A, Jones SC, Meyer T, et al. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann Intern Med. 2017;166(11):792-8. doi: 10.7326/M17-0377. [PubMed: 28437794].
  • 21. Sulkowski MS, Chuang WL, Kao JH, Yang JC, Gao B, Brainard DM, et al. No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection. Clin Infect Dis. 2016;63(9):1202-4. doi: 10.1093/cid/ciw507. [PubMed: 27486112].
  • 22. Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, et al. Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents. Clin Gastroenterol Hepatol. 2017;15(1):132-6. doi: 10.1016/j.cgh.2016.06.023. [PubMed: 27392759].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments